2000 Volume 91 Issue 5 Pages 501-505
(Purpose) Our purpose of this study was to evaluate the effect of a transdermal estradiol delivery system in postmenopausal women with confirmed pollakisuria and urinary incontinence.
(Patients and Methods) We investigated 10 postmenopausal women, age 54-83 years, with pollakisuria and urinary incontinence but did not show distinct urological and/or neurological abnormalities. In this study, estradiol transdermal therapeutic system (Estraderm TTS® 2mg) alone were administrated for total of 8-week and this is observatinal, not randomized, blinded or controlled. A clinical evaluation were performed two times at before and after administration.
(Results) In seven eligible cases, the severity of urinary incontinence was graded down in almost of them and the therapeutic effect on urinary incontinence was evaluated as “very effective” in 3 cases, “improved” in 2, “slightly improved” in 1 and “no change” in 1, respectively. In three eligible cases, the severity of pollakisuria was no change in all of them.
(Conclusion) Thus, the estrogen supplement therapy was considered effective for postmenopausal urinary incontinence.
